Landos Biopharma, Inc.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for autoimmune diseases. The company's lead product candidates include omilancor and NX-13, targeting ulcerative colitis and Crohn's disease, and LABP-104 for systemic lupus erythematosus and rheumatoid arthritis. Additionally, the company has preclinical candidates such as LABP-66 for multiple sclerosis and Alzheimer's disease, LABP-69 for diabetic nephropathy and RA, LABP-73 for asthma and chronic obstructive pulmonary disease, and LABP-111 for nonalcoholic steatohepatitis and type 1 diabetes.

Products

• Omilancor

• NX-13

• LABP-104

• LABP-66

• LABP-69

• LABP-73

• LABP-111